Phaseline

Companies › Amplia Therapeutics

Amplia Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AMP945
focal adhesion kinase (FAK) inhibitor
PTK2Phase 1Pancreatic CancerFeb 2027
narmafotinib
focal adhesion kinase (FAK) inhibitor
FAKPhase 1Pancreatic Cancer MetastaticJul 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05355298AMP945Phase 1Pancreatic CancerOncologyFeb 2027
NCT07026279narmafotinibPhase 1Pancreatic Cancer MetastaticOncologyJul 2029

Targets

FAK (1) PTK2 (1)

Companies with the same targets

Ascentage Pharma Group InxMed (Shanghai) Verastem

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.